NASDAQ Stocks
· Jun 14, 2025 2:50 PM EDT
Not market news
Celldex Therapeutics Reports 77% Angioedema-Free Rate at Week 52 in Phase 2 Trial of Barzolvolimab for Chronic Spontaneous Urticaria
Barzolvolimab significantly reduced angioedema symptoms in CSU patients after 52 weeks, demonstrating clinical efficacy and improved quality of life.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
